New drug trial aims to slow rare Cancer's spread
NCT ID NCT06571734
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called zanzalintinib (XL092) in 29 people with advanced leiomyosarcoma that has spread or cannot be removed by surgery. The drug works by blocking signals that help cancer cells grow. The goal is to see if it can slow the cancer's progression longer than current treatments, which typically work for only 4-6 months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BONE SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Northwestern University
RECRUITINGChicago, Illinois, 60611, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can engineered immune cells tackle childhood sarcoma?
- Smartwatch exercise plan aims to rebuild fitness in young cancer survivors
- A simple blood test may reveal how ewing sarcoma responds to therapy
- Experimental combo aims to tackle Treatment-Resistant cancers
- Targeted radiation zaps childhood brain tumors in early trial